In Switching Generic 'Reviews' To 'Assessments' Is US FDA Changing More Than Just A Word?
Executive Summary
MaPP revision may be just a better description of ANDA evaluations – or indicative of a broad culture change, experts tell the Pink Sheet.
You may also be interested in...
Vocabulary Change: CDER Eliminating 'Review' For NDAs And BLAs
Like ANDA evaluations, US FDA plans to use the word assessment to describe them for NDAs and BLAs.
Opioid, NME, And Generic Drugs Changes Plotted In US FDA's 2018 Policy Roadmap
‘Better informed patients,’ ‘drug competition,’ ‘biosimilar innovation’ – as well as nutrition and tobacco goals will be achieved through guidances, promotional plans and other items FDA will develop over the next year.
Opioid, NME, And Generic Drugs Changes Plotted In US FDA's 2018 Policy Roadmap
‘Better informed patients,’ ‘drug competition,’ ‘biosimilar innovation’ – as well as nutrition and tobacco goals will be achieved through guidances, promotional plans and other items FDA will develop over the next year.